ERBB3 and cancer: Furthermore, we found that HER3 inactivating antibody increase the response to anti-PD-1 treatment, and that HER3 and PD-1 co-targeting results in prolonged cancer remission in most treated animals, thus revealing a promising combination treatment option for HNSCC.